The digital transformation of pharmaceutical companies is imperative, and the pharmaceutical equipment industry shoulders a major mission

[ Market analysis of chemical machinery equipment network ] In recent years, traditional large pharmaceutical companies such as GSK, Roche, Novartis, and AstraZeneca have accelerated their digital transformation process.
Compared with the situation of domestic pharmaceutical companies, the digital transformation of domestic pharmaceutical companies is still in the preliminary stage and there are fewer mature models.
However, affected by the epidemic this year, more and more traditional pharmaceutical companies have realized that digital transformation is imperative.
In the process of digital transformation of pharmaceutical companies, the pharmaceutical equipment industry will shoulder a major mission.

Digital transformation of pharmaceutical companies is imperative
 

Data shows that since the beginning of this year, major pharmaceutical companies have significantly increased their investment in digital construction.
In 2019, digital-related costs accounted for more than 10% of total product input costs, accounting for 23% of pharmaceutical companies, and by March 2020 , This proportion increased to 40%.

 

It is understood that digital transformation includes R&D, production, marketing and other aspects.
In the production stage, the core of digitalization is to achieve standardized management.
The core of pharmaceutical production is to constrain the standardization and compliance of production personnel, so that they can be produced in accordance with standards and specifications, and optimized on this basis as much as possible.

 

　　At present, some traditional pharmaceutical companies that have not been involved in digitalization are more worried about the huge investment required for digital transformation of production.
"The current situation of my country's pharmaceutical industry is small, scattered, and low.
As a small and medium-sized enterprise, it is often difficult to afford the huge costs and risks of transformation.
Once a detour is made, it will be a waste of water.
" Some pharmaceutical company personnel said.

 

　　In the eyes of industry professionals, transformation does not mean large projects and large investments.
"Small and medium-sized enterprises can start with partial technological transformation and improvement, try from one workshop and one production line, and gradually realize the replication of the workshop and even the group's digital transformation plan.
"
 

　　In fact, the policy has also given some support to SMEs.
For example, in May of this year, 17 ministries and commissions jointly launched the "Digital Transformation Partnership Action (2020)", which aimed at small, medium and micro enterprises’ lack of capabilities, “will not turn”, high costs, “not turn”, and long-term pains, “don’t dare Encourage the gathering of the forces of the whole society to promote the implementation of partner actions by creating a good atmosphere; creatively propose to create "virtual industrial parks" and "virtual industrial clusters" that cross physical boundaries, and to break through the limitations of geographic space, and achieve One-time investment and repeated use can effectively reduce the cost of enterprise digital transformation.

 

　　At present, some pharmaceutical companies have already tasted the sweetness through digital transformation of production in advance.
For example, two pharmaceutical companies completed intelligent transformation in 2019.
Through the construction of digital workshops for oral liquid preparations, Chinese medicine extraction and solid preparations of Chinese medicine, a total of 100 sets of automated equipment were installed, which promoted an increase in production efficiency by 39% and a product qualification rate.
Increased to 99.
55%, and the annual production capacity of pharmaceutical drugs increased to 1.
8 billion.

 

　　It is understood that at the beginning of this year, due to the impact of a special period, many pharmaceutical companies have delayed the resumption of work and production.
These two pharmaceutical companies have implemented intelligent transformations and launched smart production lines, which has reduced the difficulty of resuming work and production to a certain extent, and guarantees The needs of the medical consumer market.

 

　　The pharmaceutical equipment industry shoulders a major mission
 

　　Intelligence, big data, and the Internet are becoming the development direction of the pharmaceutical industry.
The industry generally believes that in the future, the operation trend of the workshop will be unmanned.
In this context, as the mother machine of pharmaceutical production, the pharmaceutical equipment industry also shoulders a major mission and urgently needs to transform and upgrade to help solve the pain points of pharmaceutical companies.

 

　　"We are also constantly updating in this regard, and constantly improving the quality of our products.
Now there are some cases, and the company will develop in the direction they want according to the requirements provided by customers.
" A pharmaceutical machine staff accepts the pharmaceutical industry.
Said in an interview with the net.

 

　　At present, a common problem in most pharmaceutical companies is that it is difficult to strictly guarantee the pharmaceutical level.
Because more than 90% of domestic pharmaceutical companies rely on manual labor for the management and operation of the entire workshop, process instability and batch instability often occur, so it is difficult for pharmaceutical companies to fully guarantee their overall pharmaceutical level.

 

　　In this regard, some companies said that in response to this market pain point, the company provides end-to-end digital solutions for pharmaceutical companies, aiming to make up for the shortcomings of pharmaceutical companies in the management of pharmaceutical workshops and meet the current development needs of domestic pharmaceutical companies.
"On the production side, we will provide pharmaceutical companies with intelligent solutions for pharmaceutical production to solve electronic batch records (EBR), production traceability, production execution, quality control, etc.
as the core pharmaceutical manufacturing execution system to help pharmaceutical companies in management Compliance, process precipitation, quality improvement and other aspects improve management, accumulate big data, and help pharmaceutical companies achieve safety assurance and sustainable development capabilities.
" The company's personnel said.

 

　　In addition, there are also pharmaceutical machinery companies dedicated to providing overall solutions, including project services in the entire life cycle from conceptual design to later project implementation, on-site installation and commissioning, and verification services.
For example, for the production of oral liquid preparations, the company can provide overall solutions for smart oral preparations.

 

　　It is reported that this set of solutions consists of five core functional modules: digital extraction workshop, automated preparation workshop, robotic packaging workshop, raw and auxiliary material three-dimensional warehouse and logistics system, information and data center, with high-efficiency and energy-saving process equipment system and robot production line.
As the foundation, the information system as the core, and the automated logistics as the link, through the industrial Internet, the interconnection and efficient coordination of the whole process of traditional Chinese medicine production from pre-processing and extraction to product packaging has been realized, and a big data integration platform for traditional Chinese medicine production has been constructed, which integrates process equipment and control The information of the system and software system is seamlessly integrated into a digital pharmaceutical factory model, which realizes the effective integration of various data from the process equipment, production lines, and workshops of the whole factory, and meets the requirements of high efficiency, high quality, safety, and environmental protection in the production and operation of traditional Chinese medicine.
The safe and compliant production of pharmaceuticals provides a solid guarantee.

 

　　Conclusion
 

　　In general, with the advancement of policies such as consistency evaluation, mass procurement, and medical insurance control fees, pharmaceutical companies’ profit margins have been further compressed, and cost control has become a major challenge.
In addition, in the face of fierce market competition, digital transformation has become a major challenge.
The importance has become more prominent.
If pharmaceutical companies are accelerating their entry into the digital camp and empower themselves with information technology and big data, then technical equipment and solution providers such as pharmaceutical equipment companies are powerful players on the way to digital transformation.
Guaranteed.

 

　　Original title: The digital transformation of pharmaceutical companies is imperative, and the pharmaceutical equipment industry shoulders a major mission